{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:17:04Z","timestamp":1791897424249,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Context<\/jats:title>\n                <jats:p>Cushing\u2019s disease (CD) is rare condition burdened by several systemic complications correlated to higher mortality rates. The primary goal of clinicians is to achieve remission, but it is unclear if treatment can also increase life expectancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To assess the prevalence of cortisol-related complications and mortality in a large cohort of CD patients attending a single referral centre.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>The clinical charts of CD patients attending a referral hospital between 2001 and 2021 were reviewed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>126 CD patients (median age at diagnosis 39\u00a0years) were included. At the last examination, 78\/126 (61.9%) of the patients were in remission regardless of previous treatment strategies. Patients in remission showed a significant improvement in all the cardiovascular (CV) comorbidities (p\u2009&lt;\u20090.05). The CV events were more frequent in older patients (p\u2009=\u20090.003), smokers and persistent CD groups (p\u2009&lt;\u20090.05). Most of the thromboembolic (TE) and infective events occurred during active stages of the disease. The CV events were the most frequent cause of death. The standardized mortality ratio (SMR) resulted increased in persistent cases at the last follow-up (SMR 4.99, 95%CI [2.15; 9.83], p\u2009&lt;\u20090.001) whilst it was not higher in those in remission (SMR 1.66, 95%CI [0.34; 4.85], p\u2009=\u20090.543) regardless of the timing or number of treatments carried out. A younger age at diagnosis (p\u2009=\u20090.005), a microadenoma (p\u2009=\u20090.002), and remission status at the last follow-up (p\u2009=\u20090.027) all increased survival. Furthermore, an elevated number of comorbidities, in particular arterial hypertension, increased mortality rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with active CD presented a poor survival outcome. Remission restored the patients\u2019 life expectancy regardless of the timing or the types of treatments used to achieve it. Persistent CD-related comorbidities remained major risk factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-023-01343-2","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T19:03:16Z","timestamp":1690398196000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre"],"prefix":"10.1007","volume":"26","author":[{"given":"Alessandro","family":"Mondin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"issue":"2","key":"1343_CR1","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.beem.2020.101380","volume":"34","author":"M Barbot","year":"2020","unstructured":"Barbot M, Zilio M, Scaroni C (2020) Cushing\u2019s syndrome: overview of clinical presentation, diagnostic tools and complications. Best Pract Res ClinEndocrinolMetab 34(2):101380. https:\/\/doi.org\/10.1016\/j.beem.2020.101380","journal-title":"Best Pract Res ClinEndocrinolMetab"},{"issue":"2","key":"1343_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-016-0914-9","volume":"55","author":"V Guarnotta","year":"2017","unstructured":"Guarnotta V, Amato MC, Pivonello R et al (2017) The degree of urinary hypercortisolism is not correlated with the severity of cushing\u2019s syndrome. Endocrine 55(2):564\u2013572. https:\/\/doi.org\/10.1007\/s12020-016-0914-9","journal-title":"Endocrine"},{"issue":"12","key":"1343_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1343_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11102-022-01254-8","volume":"25","author":"PS Jones","year":"2022","unstructured":"Jones PS, Swearingen B (2022) Pituitary surgery in Cushing\u2019s disease: first line treatment and role of reoperation. Pituitary 25(5):713\u2013717. https:\/\/doi.org\/10.1007\/s11102-022-01254-8","journal-title":"Pituitary"},{"issue":"3","key":"1343_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1210\/jc.2006-2112","volume":"92","author":"OM Dekkers","year":"2007","unstructured":"Dekkers OM, Biermasz NR, Pereira AM et al (2007) Mortality in patients treated for Cushing\u2019s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J ClinEndocrinolMetab 92(3):976\u2013981. https:\/\/doi.org\/10.1210\/jc.2006-2112","journal-title":"J ClinEndocrinolMetab"},{"issue":"4","key":"1343_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1210\/jc.2011-2957","volume":"97","author":"ZK Hassan-Smith","year":"2012","unstructured":"Hassan-Smith ZK, Sherlock M, Reulen RC et al (2012) Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years. J ClinEndocrinolMetab 97(4):1194\u20131201. https:\/\/doi.org\/10.1210\/jc.2011-2957","journal-title":"J ClinEndocrinolMetab"},{"issue":"5","key":"1343_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-13-0320","volume":"169","author":"M Yaneva","year":"2013","unstructured":"Yaneva M, Kalinov K, Zacharieva S (2013) Mortality in Cushing\u2019s syndrome: data from 386 patients from a single tertiary referral center. Eur J Endocrinol. 169(5):621\u2013627. https:\/\/doi.org\/10.1530\/EJE-13-0320","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"1343_CR8","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1210\/clinem\/dgaa774","volume":"106","author":"P Rold\u00e1n-Sarmiento","year":"2021","unstructured":"Rold\u00e1n-Sarmiento P, Lam-Chung CE, Hinojosa-Amaya JM et al (2021) Diabetes, active disease, and afternoon serum cortisol levels predict cushing\u2019s disease mortality: a cohort study. J ClinEndocrinolMetab 106(1):e103\u2013e111. https:\/\/doi.org\/10.1210\/clinem\/dgaa774","journal-title":"J ClinEndocrinolMetab"},{"issue":"8","key":"1343_CR9","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch P, Morgan AW, Tiganescu A et al (2022) The effect of endogenous cushing syndrome on all-cause and cause-specific mortality. J ClinEndocrinolMetab 107(8):2377\u20132388. https:\/\/doi.org\/10.1210\/clinem\/dgac265","journal-title":"J ClinEndocrinolMetab"},{"issue":"6","key":"1343_CR10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1210\/jc.2018-02524","volume":"104","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson O, Olsson DS, Papakokkinou E et al (2019) Overall and disease-specific mortality in patients with cushing disease: a swedish nationwide study. J ClinEndocrinolMetab 104(6):2375\u20132384. https:\/\/doi.org\/10.1210\/jc.2018-02524","journal-title":"J ClinEndocrinolMetab"},{"key":"1343_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac045","author":"D Bengtsson","year":"2022","unstructured":"Bengtsson D, Ragnarsson O, Berinder K et al (2022) Increased mortality persists after treatment of cushing\u2019s disease: a matched nationwide cohort study. J Endocr Soc. https:\/\/doi.org\/10.1210\/jendso\/bvac045","journal-title":"J Endocr Soc"},{"issue":"7","key":"1343_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569\u2013576. https:\/\/doi.org\/10.1016\/S2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1343_CR13","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J ClinEndocrinolMetab 93(5):1526\u20131540. https:\/\/doi.org\/10.1210\/jc.2008-0125","journal-title":"J ClinEndocrinolMetab"},{"issue":"2","key":"1343_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cen.12259","volume":"80","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM, Pasireotide B2305 Study Group (2014) High variability in baseline urinary free cortisol values in patients with Cushing\u2019s disease. ClinEndocrinol 80(2):261\u20139. https:\/\/doi.org\/10.1111\/cen.12259","journal-title":"ClinEndocrinol"},{"issue":"3","key":"1343_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1210\/jc.2017-02020","volume":"103","author":"Z Sandouk","year":"2018","unstructured":"Sandouk Z, Johnston P, Bunch D, Wang S, Bena J, Hamrahian A, Kennedy L (2018) Variability of late-night salivary cortisol in cushing disease: a prospective study. J ClinEndocrinolMetab 103(3):983\u2013990. https:\/\/doi.org\/10.1210\/jc.2017-02020","journal-title":"J ClinEndocrinolMetab"},{"issue":"5","key":"1343_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11102-016-0729-y","volume":"19","author":"M Barbot","year":"2016","unstructured":"Barbot M, Trementino L, Zilio M et al (2016) Second-line tests in the differential diagnosis of ACTH-dependent Cushing\u2019s syndrome. Pituitary 19(5):488\u2013495. https:\/\/doi.org\/10.1007\/s11102-016-0729-y","journal-title":"Pituitary"},{"issue":"3","key":"1343_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cen.12133","volume":"79","author":"M Barbot","year":"2013","unstructured":"Barbot M, Albiger N, Koutroumpi S et al (2013) Predicting late recurrence in surgically treated patients with Cushing\u2019s disease. ClinEndocrinol (Oxf) 79(3):394\u2013401. https:\/\/doi.org\/10.1111\/cen.12133","journal-title":"ClinEndocrinol (Oxf)"},{"issue":"3","key":"1343_CR18","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G et al (2021) Corticotrophtumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184(3):P1\u2013P16. https:\/\/doi.org\/10.1530\/EJE-20-1088","journal-title":"Eur J Endocrinol"},{"issue":"33","key":"1343_CR19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, EvgenyShlyakhto CT, Aboyans V, Desormais L, ESC Scientific Document Group (2018) ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of cardiology (ESC) and the european society of hypertension (ESH). Eur Heart J 39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"issue":"1","key":"1343_CR20","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 45(1):S17\u2013S38. https:\/\/doi.org\/10.2337\/dc22-S002","journal-title":"Diabetes Care."},{"issue":"6","key":"1343_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H, Obesity Management Task Force of the European Association for the Study of Obesity (2015) European guidelines for obesity management in adults. Obes Facts 8(6):402\u201324. https:\/\/doi.org\/10.1159\/000442721","journal-title":"Obes Facts"},{"issue":"19","key":"1343_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285(19):2486\u20132497. https:\/\/doi.org\/10.1001\/jama.285.19.2486","journal-title":"JAMA."},{"issue":"1","key":"1343_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL et al (2019) ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J."},{"issue":"11","key":"1343_CR24","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J ClinEndocrinolMetab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J ClinEndocrinolMetab"},{"issue":"3","key":"1343_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1210\/clinem\/dgz136","volume":"105","author":"G Rubinstein","year":"2020","unstructured":"Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, Machado MC, Hanzu FA, Zopp S, Ritzel K, Riester A, Braun LT, Kreitschmann-Andermahr I, Storr HL, Bansal P, Barahona MJ, Cosaro E, Dogansen SC, Johnston PC, Santos de Oliveira R, Raftopoulos C, Scaroni C, Valassi E, van der Werff SJA, Schopohl J, Beuschlein F, Reincke M (2020) Time to diagnosis in cushing\u2019s syndrome: a meta-analysis based on 5367 patients. J ClinEndocrinolMetab 105(3):12. https:\/\/doi.org\/10.1210\/clinem\/dgz136","journal-title":"J ClinEndocrinolMetab"},{"key":"1343_CR26","volume-title":"Volume II\u2013The design and analysis of cohort studies","author":"DNE BreslowNE","year":"1987","unstructured":"BreslowNE DNE (1987) Statistical methods in cancer research. Volume II\u2013The design and analysis of cohort studies. OxfordUniversity Press, New York"},{"key":"1343_CR27","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.P416","author":"A Mondin","year":"2023","unstructured":"Mondin A, Ceccato F, Voltan G et al (2023) Treatment complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. EJEA. https:\/\/doi.org\/10.1530\/endoabs.90.P416","journal-title":"EJEA"},{"issue":"3","key":"1343_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing\u2019s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J ClinEndocrinolMetab 96(3):632\u2013642. https:\/\/doi.org\/10.1210\/jc.2010-1942","journal-title":"J ClinEndocrinolMetab"},{"issue":"3","key":"1343_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1210\/jc.2012-2893","volume":"98","author":"JK Lambert","year":"2013","unstructured":"Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB (2013) Predictors of mortality and long-term outcomes in treated Cushing\u2019s disease: a study of 346 patients. J ClinEndocrinolMetab 98(3):1022\u20131030. https:\/\/doi.org\/10.1210\/jc.2012-2893","journal-title":"J ClinEndocrinolMetab"},{"issue":"2","key":"1343_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11102-015-0645-6.PMID:25724314;PMCID:PMC4374115","volume":"18","author":"ST Sharma","year":"2015","unstructured":"Sharma ST, Nieman LK, Feelders RA (2015) Comorbidities in Cushing\u2019s disease. Pituitary 18(2):188\u2013194. https:\/\/doi.org\/10.1007\/s11102-015-0645-6.PMID:25724314;PMCID:PMC4374115","journal-title":"Pituitary"},{"issue":"1","key":"1343_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"Schernthaner-Reiter MH, Siess C, Gessl A et al (2019) Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission. Endocrine. 64(1):157\u2013168. https:\/\/doi.org\/10.1007\/s12020-018-1819-6","journal-title":"Endocrine."},{"issue":"5","key":"1343_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.rec.2022.04.003","volume":"75","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2022) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task Force for cardiovascular disease prevention in clinical practice with representatives of the european society of cardiology and 12 medical societies with the special contribution of the european association of preventive cardiology (EAPC). Rev EspCardiol  75(5):429. https:\/\/doi.org\/10.1016\/j.rec.2022.04.003","journal-title":"Rev EspCardiol"},{"issue":"8","key":"1343_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1210\/clinem\/dgaa291","volume":"105","author":"E Papakokkinou","year":"2020","unstructured":"Papakokkinou E, Olsson DS, Chantzichristos D, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, H\u00f6ybye C, Ed\u00e9n-Engstr\u00f6m B, Burman P, Bonelli L, Follin C, Petranek D, Erfurth EM, Wahlberg J, Ekman B, \u00c5kerman AK, Schwarcz E, Bryngelsson IL, Johannsson G, Ragnarsson O (2020) Excess morbidity persists in patients with cushing\u2019s disease during long-term remission: a swedish nationwide study. J ClinEndocrinolMetab. 105(8):291. https:\/\/doi.org\/10.1210\/clinem\/dgaa291","journal-title":"J ClinEndocrinolMetab."},{"issue":"4","key":"1343_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","volume":"18","author":"M Barbot","year":"2015","unstructured":"Barbot M, Daidone V, Zilio M, Albiger N, Mazzai L, Sartori MT, Frigo AC, Scanarini M, Denaro L, Boscaro M, Casonato S, Ceccato F, Scaroni C (2015) Perioperative thromboprophylaxis in Cushing\u2019s disease: what we did and what weare doing? Pituitary 18(4):487\u2013493. https:\/\/doi.org\/10.1007\/s11102-014-0600-y","journal-title":"Pituitary"},{"issue":"9","key":"1343_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fendo.2018.00284","volume":"5","author":"M Barbot","year":"2018","unstructured":"Barbot M, Ceccato F, Scaroni C (2018) Diabetes mellitus secondary to cushing\u2019s disease. Front Endocrinol 5(9):284. https:\/\/doi.org\/10.3389\/fendo.2018.00284","journal-title":"Front Endocrinol"},{"issue":"9996","key":"1343_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, StratakisCA NLK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927. https:\/\/doi.org\/10.1016\/S0140-6736(14)61375-1","journal-title":"Lancet"},{"issue":"3","key":"1343_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s11102-022-01215-1","volume":"25","author":"C Perez-Vega","year":"2022","unstructured":"Perez-Vega C, Ramos-Fresnedo A, Tripathi S, Domingo RA, Ravindran K, Almeida JP, Peterson J, Trifiletti DM, Chaichana KL, Quinones-Hinojosa A, Samson SL (2022) Treatment of recurrent and persistent Cushing\u2019s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis. Pituitary 25(3):540\u2013549. https:\/\/doi.org\/10.1007\/s11102-022-01215-1","journal-title":"Pituitary"},{"issue":"4","key":"1343_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","volume":"178","author":"E Valassi","year":"2018","unstructured":"Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, Tsagarakis S, Webb SM, Yaneva M, Reincke M, Droste M, Komerdus I, Maiter D, Kastelan D, Chanson P, Pfeifer M, Strasburger CJ, T\u00f3th M, Chabre O, Krsek M, Fajardo C, Bolanowski M, Santos A, Trainer PJ, Wass JAH, Tabarin A, ERCUSYN Study Group (2018) Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur J Endocrinol 178(4):399\u2013409. https:\/\/doi.org\/10.1530\/EJE-17-0997","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1343_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3)","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, Mantero F, Scaroni C (2014) Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 17(2):109\u2013117. https:\/\/doi.org\/10.1007\/s11102-013-0475-3)","journal-title":"Pituitary"},{"issue":"4","key":"1343_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-012-0452-2","volume":"16","author":"R van der Pas","year":"2013","unstructured":"van der Pas R, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Webb SM, Lamberts SW, Hofland LJ, Feelders RA (2013) Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing\u2019s disease. Pituitary 16(4):536\u2013544. https:\/\/doi.org\/10.1007\/s11102-012-0452-2","journal-title":"Pituitary"},{"issue":"2","key":"1343_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-016-0978-6","volume":"54","author":"JW Findling","year":"2016","unstructured":"Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM (2016) Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing\u2019s disease: 12-month. Phase III Pasireotide Study Endocrine 54(2):516\u2013523. https:\/\/doi.org\/10.1007\/s12020-016-0978-6","journal-title":"Phase III Pasireotide Study Endocrine"},{"issue":"2","key":"1343_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR et al (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182(2):207\u201317","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1343_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W et al (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J ClinEndocrinolMetab 101(2):364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J ClinEndocrinolMetab"},{"issue":"1","key":"1343_CR44","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(1):101521. https:\/\/doi.org\/10.1016\/j.beem.2021.101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"1343_CR45","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.3275\/7349","volume":"34","author":"NM Albiger","year":"2011","unstructured":"Albiger NM, Occhi G, Sanguin F, Iacobone M, Casarrubea G, Ferasin S, Mantero F, Scaroni C (2011) Adrenal nodules in patients with Cushing\u2019s disease: prevalence, clinical significance and follow-up. J Endocrinol Invest 34(8):e204\u2013e209. https:\/\/doi.org\/10.3275\/7349","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1343_CR46","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1210\/jc.2018-02209","volume":"104","author":"G Di Dalmazi","year":"2019","unstructured":"Di Dalmazi G, Timmers HJLM, Arnaldi G et al (2019) Somatic PRKACA mutations: association with transition from pituitary-dependent to adrenal-dependent cushing syndrome. J ClinEndocrinolMetab 104(11):5651\u20135657. https:\/\/doi.org\/10.1210\/jc.2018-02209","journal-title":"J ClinEndocrinolMetab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01343-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01343-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01343-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:12:34Z","timestamp":1695885154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01343-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01343-2","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"14 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matters discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The current study was designed in accordance with the principles of the Declaration of Helsinki and approved by the Ethical Committee of the province of Padova (protocol code 236n\/AO\/22, date of approval 29 April 2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}